Literature DB >> 20509562

[Diagnosis and venom specific immunotherapy (VIT) in allergic children in Poland--how much the current practice follows the international guidelines?].

Ewa Cichocka-Jarosz1, Piotr Brzyski, Grzegorz Lis, Urszula Jedynak-Wasowicz, Jacek Józef Pietrzyk, Joanna Lange, Teresa Małaczyńska, Barbara Kraluk, Ewa Swiebocka, Anna Breborowicz, Zdzisława Kycler, Jolanta Pietraszek-Mamcarz, Adam Poszwiński, Grzegorz Gaszczyk.   

Abstract

INTRODUCTION: Insect venom allergy requires a high level approach adequate to allergy intensity. In case of severe IgE-mediated sting reactions, in children older than five years, venom immunotherapy is a treatment of choice. AIM: Identification of current practices applied to venom allergic children in Poland and their adherence to the international guidelines.
METHOD: Questionnaire survey concerning diagnostic and treatment rules was carried out in 8 centres of pediatric allergology, based on a similar audit conducted in the United Kingdom [Diwakar L. et al. Clin Exp Allergy 2008, 38: 1651].
RESULTS: In 5 centres both RAST and SPT tests were used as the first line of investigation. Subsequently 6 centres performed IDT. In three centres baseline serum tryptase levels were estimated. In case of sensitization to both bee and wasp venom in a child with the history of severe systemic reaction, but uncertain culprit insect, specific venom immunotherapy with both venoms was practised by 2 centres. In systemic reaction and not-detectable IgE in 6 centres child was followed-up in 6-12 months. Antihistamine premedication concerned all children in 7 centres. Six-week interval between booster doses was applied in half of centres. A target dose equal 100 mcg was used in 7 centres. Similarly all centres practiced 3-5 five year period of VIT.
CONCLUSIONS: In Poland current practice with venom allergic children was conducted in congruence with most of the recommendations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20509562

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  2 in total

1.  Congruence of the current practices in Hymenoptera venom allergic patients in Poland with EAACI guidelines.

Authors:  Ewa Cichocka-Jarosz; Lavanya Diwakar; Piotr Brzyski; Beata Tobiasz-Adamczyk; Grzegorz Lis; Jacek J Pietrzyk
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

2.  How fast does wasp venom immunotherapy affect a regulatory T cell subpopulation (CD4+ CD25+ Foxp3+) and the synthesis of interleukins 10, 21 and transforming growth factor β1?

Authors:  Aleksander Zakrzewski; Jerzy Kruszewski; Andrzej Chciałowski; Krzysztof Kłos; Agnieszka Rzeszotarska; Jolanta Korsak; Ewa M Nowosielska; Aneta Cheda; Jolanta Wrembel-Wargocka; Marek K Janiak
Journal:  Postepy Dermatol Alergol       Date:  2019-02-22       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.